Glutamatergic changes in the cerebral white matter associated with schizophrenic exacerbation

Acta Psychiatrica Scandinavica

Volumn 126, Issue 1, 2012, Pages 72-78

  Ota, M ^a   Ishikawa, M ^b   Sato, N ^b   Hori, H ^a   Sasayama, D ^a   Hattori, K ^a   Teraishi, T ^a   Nakata, Y ^b   Kunugi, H ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

Exacerbation; Glutamine+glutamate; Magnetic resonance spectroscopy; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; GLYCEROPHOSPHORYLCHOLINE; INOSITOL; NEUROLEPTIC AGENT; PHOSPHORYLCHOLINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FRONTAL LOBE; HUMAN; INFERIOR PARIETAL LOBULE; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; WHITE MATTER;

ADULT; BRAIN; BRAIN CHEMISTRY; CASE-CONTROL STUDIES; DISEASE PROGRESSION; EXCITATORY AMINO ACIDS; FEMALE; GLUTAMIC ACID; GLUTAMINE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEUROIMAGING; PARIETAL LOBE; SCHIZOPHRENIA;

EID: 84862120952     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2012.01853.x     Document Type: Article

References (36)

1. Tsai G, van Kammen DP, Chen S, Kelley ME, Grier A, Coyle JT. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol Psychiatry 1998;44:667-674.
2. Bartha R, Williamson PC, Drost DJ et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1997;54:959-965.
3. Theberge J, Bartha R, Drost D et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 2002;159:1944-1946.
4. Kegeles LS, Mao X, Stanford AD et al. Elevated Prefrontal Cortex γ-Aminobutyric Acid and Glutamate-Glutamine Levels in Schizophrenia Measured In Vivo With Proton Magnetic Resonance Spectroscopy. Arch Gen Psychiatry 2012;69:449-459.
5. Marsman A, van den Heuvel MP, Klomp DW et al. Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies. Schizophr Bull 2011; doi: 10.1093/schbul/sbr069 [Epub ahead of print].
6. Theberge J, Al-Semaan Y, Williamson P et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 2003;160:2231-2233.
7. Matute C, Domercq M, Sanchez-Gomez MV. Glutamate-mediated glial injury: mechanisms and clinical importance. Glia 2006;53:212-224.
8. Mcdonald JW, Althomsons SP, Hyre KL, Choi DW, Goldber MP. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med 1998;4:291-297.
9. Hyde TM, Ziegler JC, Weinberger DR. Psychiatric disturbance in metachromatic leukodystrophy. Insights into the neurobiology of psychosis. Arch Neurol 1992;49:401-406.
10. Christensen J, Holcomb J, Garver DL. State-related changes in cerebral white matter may underlie psychosis exacerbation. Psychiatry Res 2004;130:71-78.
11. Olney JW, Farber NB. Glutamate receptor dysfunction in schizophrenia. Arch Gen Psychiatry 1995;52:998-1007.
12. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367-1377.
13. Rowland LM, Spieker EA, Francis A, Barker PB, Carpenter WT, Buchanan RW. White matter alterations in deficit schizophrenia. Neuropsychopharmacology 2009;34:1514-1522.
14. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th edn, Washington, DC: American Psychiatric Press, 1994.
15. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) manual. Schizophr Bull 1987;13:261-276.
16. Xiang YQ, Zhang ZJ, Weng YZ et al. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophr Res 2006;83:201-210.
17. Canuso CM, Dirks B, Carothers J et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 2006;166:691-701.
18. Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59:22-57.
19. Otsubo T, Tanaka K, Koda R, Shinoda J, Sano N, Tanaka S. Reliability and validity of Japanese version of the Mini-International Neuropsychiatric Interview. Psychiatry Clin Neurosci 2005;59:517-526.
20. American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Schizophrenia. Washington, DC: American Psychiatric Press, 1997.
21. Inagaki A, Inada T, Fujii Y, Yagi G. Equivalent Dose of Psychotropics. Tokyo: Seiwa Shoten, 1999.
22. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679.
23. Theberge J, Williamson KE, Aoyama N et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry 2007;191:325-354.
24. Choe BY, Kim KT, Suh TS et al. 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia. Acad Radiol 1994;1:211-216.
25. van Elst LT, Valerius G, Buchert M et al. Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry 2005;58:724-730.
26. Pakkenberg B, Scheel-Kruger J, Kristiansen LV. Schizophrenia; from structure to function with special focus on the mediodorsal thalamic prefrontal loop. Acta Psychiatr Scand 2009;120:345-354.
27. Tibbo P, Hanstock C, Valiakalayil A, Allen P. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry 2004;161:1116-1118.
28. Rothman DL, Sibson NR, Hyder F. In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics. Philos Trans R Soc London B Biol Sci 1999;354:1165-1167.
29. Carlsson A, Hansson LO, Waters N. A glutamatergic deficiency model of schizophrenia. Br J Psychiatry 1999;174:2-6.
30. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-1308.
31. Rowland LM, Bustillo JR, Mullins PG et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 2005;162:394-396.
32. Keshavan MS. Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. J Psychiatr Res 1999;33:513-521.
33. Thompson PM, Vidal C, Giedd JN et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. PNAS 2001;98:11650-11655.
34. Hubl D, Koenig T, Strik W et al. Pathways that make voices: white matter changes in auditory hallucinations. Arch Gen Psychiatry 2004;61:658-668.
35. Nielsen J, Le Quach P, Emborg C et al. 10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr Scand 2010;122:356-366.
36. Bustillo JR, Rowland LM, Mullins P et al. 1H-MRS at 4 Tesla in minimally treated early schizophrenia. Mol Psychiatry 2010;15:629-636.